PPARγ Agonists as Therapeutics for the Treatment of Alzheimer's Disease

Neurotherapeutics

Volumn 5, Issue 3, 2008, Pages 481-489

  Landreth, Gary ^a   Jiang, Qingguang ^a   Mandrekar, Shweta ^a   Heneka, Michael ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Alzheimer's disease; amyloid beta; apolipoprotein E; inflammation; Peroxisome proliferator activated receptor gamma; thiazolidinedione

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; IBUPROFEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; ROSIGLITAZONE; NEUROLEPTIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COGNITION; DRUG EFFICACY; DRUG TARGETING; DYSLIPIDEMIA; GENE EXPRESSION; HUMAN; INFLAMMATION; INSULIN SENSITIVITY; LEARNING; MEMORY; NONHUMAN; PRIORITY JOURNAL; TRANSACTIVATION; ANIMAL; DRUG POTENTIATION; METABOLISM; REVIEW;

ALZHEIMER DISEASE; ANIMALS; ANTIPSYCHOTIC AGENTS; HUMANS; PPAR GAMMA;

EID: 46749115113     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2008.05.003     Document Type: Article

References (121)

1. Sundararajan S., Jiang Q., Heneka M., et al. PPARgamma as a therapeutic target in central nervous system diseases. Neurochem Int 49 (2006) 136-144
2. Risner M.E., Saunders A.M., Altman J.F., et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J 6 (2006) 246
3. Kersten S., Desvergne B., and Wahli W. Roles of PPARs in health and disease. Nature 405 (2000) 421-424
4. Bookout A.L., Jeong Y., Downes M., et al. Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell 126 (2006) 789-799
5. Lehrke M., and Lazar M. The many faces of PPARgamma. Cell (Cambridge) 123 (2005) 993-999
6. Maeshiba Y., Kiyota Y., Yamashita K., et al. Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys. Arzneimittelforschung 47 (1997) 29-35
7. Pedersen W., McMillan P., Kulstad J., et al. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp Neurol 199 (2006) 265-273
8. Strum J.C., Shehee R., Virley D., et al. Rosiglitazone induces mitochondrial biogenesis in mouse brain. J Alzheimers Dis 11 (2007) 45-51
9. Glass C.K. Going nuclear in metabolic and cardiovascular disease. Eur J Clin Invest 116 (2006) 556-560
10. Berger J., and Moller D.E. The mechanisms of action of PPARs. Annu Rev Med 53 (2002) 409-435
11. Aranda A., and Pascual A. Nuclear hormone receptors and gene expression. Physiol Rev 81 (2001) 1269-1304
12. Glass C.K., and Rosenfeld M.G. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 14 (2000) 121-141
13. Daynes R.A., and Jones D.C. Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2 (2002) 748-759
14. Subbaramaiah K., Lin D.T., Hart J.C., et al. Peroxisome Proliferator-activated receptor gamma ligands suppress the transcriptional activation of cyclooxygenase-2: evidence for involvement of activator protein-1 and CREB-binding protein/p300. J Biol Chem 276 (2001) 12440-12448
15. Li M., Pascual G., and Glass C.K. Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene. Mol Cell Biol 20 (2000) 4699-4707
16. Pascual G., Fong A.L., Ogawa S., et al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 437 (2005) 759-763
17. Yan Q., Zhang J., Liu H., et al. Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci 23 (2003) 7504-7509
18. Lim G.P., Yang F., Chu T., et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci 20 (2000) 5709-5714
19. Heneka M., Sastre M., Dumitrescu-Ozimek L., et al. Acute treatment with the PPARg agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain 128 (2005) 1442-1453
20. Pedersen W.A., and Flynn E.R. Insulin resistance contributes to aberrant stress responses in the Tg2576 mouse model of Alzheimer's disease. Neurobiol Dis 17 (2004) 500-506
21. Andrews R., and Walker B. Glucocorticoids and insulin resistance: old hormones, new targets. Clinical science (London, England: 1979) 96 (1999) 513-523
22. Andrews R.C., Herlihy O., Livingstone D.E., et al. Abnormal cortisol metabolism and tissue sensitivity to cortisol in patients with glucose intolerance. J Clin Endocrinol Metab 87 (2002) 5587-5593
23. Pomara N., Greenberg W.M., Branford M.D., et al. Therapeutic implications of HPA axis abnormalities in Alzheimer's disease: review and update. Psychopharmacol Bull 37 (2003) 120-134
24. Morcos M., Fohr B., Tafel J., et al. Long-term treatment of central Cushing's syndrome with rosiglitazone. Exp Clin Endocrinol Diabetes 115 (2007) 292-297
25. Ambrosi B., Dall'Asta C., Cannavo S., et al. Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease. Eur J Endocrinol 151 (2004) 173-178
26. Heaney A.P., Fernando M., Yong W.H., et al. Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med 8 (2002) 1281-1287
27. Catrina S.B., Virtanen K., Hallsten K., et al. Effect of rosiglitazone on early-morning plasma cortisol levels. Neuro Endocrinol Lett 26 (2005) 763-764 author reply 765
28. Watson G.S., Cholerton B.A., Reger M.A., et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 13 (2005) 950-958
29. Geldmacher D, Fritsch T, McClendon M, et al. A pilot study of pioglitazone in Alzheimer Disease. Int Conf Alz Dis Rel. Dementias; Madrid, July, 2006.
30. Waugh J., Keating G.M., Plosker G.L., et al. Pioglitazone: a review of its use in type 2 diabetes mellitus. Drugs 66 (2006) 85-109
31. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007) 2457-2471
32. Lincoff A.M., Wolski K., Nicholls S.J., et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298 (2007) 1180-1188
33. Kuusisto J., Koivisto K., Mykkanen L., et al. Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study. BMJ 315 (1997) 1045-1049
34. Craft S., Asthana S., Schellenberg G., et al. Insulin metabolism in Alzheimer's disease differs according to apolipoprotein E genotype and gender. Neuroendocrinology 70 (1999) 146-152
35. Craft S., Asthana S., Schellenberg G., et al. Insulin effects on glucose metabolism, memory, and plasma amyloid precursor protein in Alzheimer's disease differ according to apolipoprotein-E genotype. Ann N Y Acad Sci 903 (2000) 222-228
36. Sastre M., Dewachter I., Landreth G.E., et al. Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J Neurosci 23 (2003) 9796-9804
37. Sastre M., Dewachter I., Rossner S., et al. Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc Natl Acad Sci U S A 103 (2006) 443-448
38. d'Abramo C., Massone S., Zingg J.M., et al. Role of peroxisome proliferator-activated receptor gamma in amyloid precursor protein processing and amyloid beta-mediated cell death. Biochem J 391 (2005) 693-698
39. Camacho I.E., Serneels L., Spittaels K., et al. Peroxisome proliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide. J Neurosci 24 (2004) 10908-10917
40. Mosconi L., Tsui W.H., De Santi S., et al. Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis. Neurology 64 (2005) 1860-1867
41. Reiman E.M., Chen K., Alexander G.E., et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A 101 (2004) 284-289
42. Reiman E.M., Caselli R.J., Chen K., et al. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc Natl Acad Sci U S A 98 (2001) 3334-3339
43. Small G.W., Ercoli L.M., Silverman D.H., et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 97 (2000) 6037-6042
44. Small G.W., Mazziotta J.C., Collins M.T., et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 273 (1995) 942-947
45. Reiman E.M., Chen K., Alexander G.E., et al. Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. Proc Natl Acad Sci U S A 102 (2005) 8299-8302
46. Bookheimer S.Y., Strojwas M.H., Cohen M.S., et al. Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med 343 (2000) 450-456
47. Castellani R., Hirai K., Aliev G., et al. Role of mitochondrial dysfunction in Alzheimer's disease. J Neurosci Res 70 (2002) 357-360
48. Roses A.D., Saunders A.M., Huang Y., et al. Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease). Pharmacogenomics J 7 (2007) 10-28
49. Bogacka I., Xie H., Bray G.A., et al. Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo. Diabetes 54 (2005) 1392-1399
50. Handschin C., and Spiegelman B.M. Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr Rev 27 (2006) 728-735
51. Hondares E., Mora O., Yubero P., et al. Thiazolidinediones and rexinoids induce peroxisome proliferator-activated receptor-coactivator (PGC)-1alpha gene transcription: an autoregulatory loop controls PGC-1alpha expression in adipocytes via peroxisome proliferator-activated receptor-gamma coactivation. Endocrinology 147 (2006) 2829-2838
52. Wu Z., Puigserver P., Andersson U., et al. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 98 (1999) 115-124
53. Kelly L.J., Vicario P.P., Thompson G.M., et al. Peroxisome proliferator-activated receptors gamma and alpha mediate in vivo regulation of uncoupling protein (UCP-1, UCP-2, UCP-3) gene expression. Endocrinology 139 (1998) 4920-4927
54. Puigserver P., Wu Z., Park C.W., et al. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92 (1998) 829-839
55. Houten S.M., and Auwerx J. PGC-1alpha: turbocharging mitochondria. Cell 119 (2004) 5-7
56. Mootha V.K., Lindgren C.M., Eriksson K.F., et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34 (2003) 267-273
57. Feinstein D.L., Spagnolo A., Akar C., et al. Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key?. Biochem Pharmacol 70 (2005) 177-188
58. Biessels G.J., Staekenborg S., Brunner E., et al. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 5 (2006) 64-74
59. Razay G., Vreugdenhil A., and Wilcock G. The metabolic syndrome and Alzheimer disease. Archives of Neurology 64 (2007) 93-96
60. Razay G., and Wilcock G.K. Hyperinsulinaemia and Alzheimer's disease. Age Ageing 23 (1994) 396-399
61. Craft S., Peskind E., Schwartz M.W., et al. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology 50 (1998) 164-168
62. Leibson C.L., Rocca W.A., Hanson V.A., et al. The risk of dementia among persons with diabetes mellitus: a population-based cohort study. Ann N Y Acad Sci 826 (1997) 422-427
63. Ott A., Stolk R.P., van Harskamp F., et al. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 53 (1999) 1937-1942
64. Xu W.L., Qiu C.X., Wahlin A., et al. Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology 63 (2004) 1181-1186
65. Arvanitakis Z., Wilson R.S., Bienias J.L., et al. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 61 (2004) 661-666
66. Peila R., Rodriguez B.L., and Launer L.J. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 51 (2002) 1256-1262
67. Haan M.N., Mungas D.M., Gonzalez H.M., et al. Prevalence of dementia in older Latinos: the influence of type 2 diabetes mellitus, stroke and genetic factors. J Am Geriatr Soc 51 (2003) 169-177
68. Willson T.M., Lambert M.H., and Kliewer S.A. Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu Rev Biochem 70 (2001) 341-367
69. Picard F., and Auwerx J. PPAR(gamma) and glucose homeostasis. Annu Rev Nutr 22 (2002) 167-197
70. Wallum B.J., Taborsky Jr. G.J., Porte Jr. D., et al. Cerebrospinal fluid insulin levels increase during intravenous insulin infusions in man. J Clin Endocrinol Metab 64 (1987) 190-194
71. Frolich L., Blum-Degen D., Riederer P., et al. A disturbance in the neuronal insulin receptor signal transduction in sporadic Alzheimer's disease. Ann N Y Acad Sci 893 (1999) 290-293
72. Messier C., and Teutenberg K. The role of insulin, insulin growth factor, and insulin-degrading enzyme in brain aging and Alzheimer's disease. Neural Plast 12 (2005) 311-328
73. Craft S., Asthana S., Cook D.G., et al. Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype. Psychoneuroendocrinology 28 (2003) 809-822
74. Craft S. Insulin resistance syndrome and Alzheimer disease: pathophysiologic mechanisms and therapeutic implications. Alzheimer Dis Assoc Disord 20 (2006) 298-301
75. Ho L., Qin W., Pompl P.N., et al. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. Faseb J 18 (2004) 902-904
76. Eckman E.A., and Eckman C.B. Abeta-degrading enzymes: modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention. Biochem Soc Trans 33 (2005) 1101-1105
77. Leissring M.A. Proteolytic degradation of the amyloid beta-protein: the forgotten side of Alzheimer's disease. Curr Alzheimer Res 3 (2006) 431-435
78. Cook D.G., Leverenz J.B., McMillan P.J., et al. Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele. Am J Pathol 162 (2003) 313-319
79. Farris W., Leissring M.A., Hemming M.L., et al. Alternative splicing of human insulin-degrading enzyme yields a novel isoform with a decreased ability to degrade insulin and amyloid beta-protein. Biochemistry (Washington) 44 (2005) 6513-6525
80. Farris W., Mansourian S., Leissring M.A., et al. Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein. Am J Pathol 164 (2004) 1425-1434
81. Farris W., Mansourian S., Chang Y., et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A 100 (2003) 4162-4167
82. Pedersen W.A., McMillan P.J., Kulstad J.J., et al. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp Neurol 199 (2006) 265-273
83. Panza F., Capurso C., D'Introno A., et al. Serum total cholesterol as a biomarker for Alzheimer's disease: mid-life or late-life determinations?. Exp Gerontol 41 (2006) 805-806
84. Notkola I.L., Sulkava R., Pekkanen J., et al. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology 17 (1998) 14-20
85. Wolozin B., Kellman W., Ruosseau P., et al. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Archives of Neurology 57 (2000) 1439-1443
86. Puglielli L., Tanzi R.E., and Kovacs D.M. Alzheimer's disease: the cholesterol connection. Nature Neuroscience 6 (2003) 345-351
87. Wollmer M.A., Streffer J.R., Lutjohann D., et al. ABCA1 modulates CSF cholesterol levels and influences the age at onset of Alzheimer's disease. Neurobiol Aging 24 (2003) 421-426
88. Hamilton G., Proitsi P., Jehu L., et al. Candidate gene association study of insulin signaling genes and Alzheimer's disease: evidence for SOS2, PCK1, and PPARgamma as susceptibility loci. Am J Med Genet B Neuropsychiatr Genet 144 (2007) 508-516
89. Scacchi R., Pinto A., Gambina G., et al. The peroxisome proliferator-activated receptor gamma (PPAR-gamma2) Pro12Ala polymorphism is associated with higher risk for Alzheimer's disease in octogenarians. Brain Res 1139 (2007) 1-5
90. Wahrle S.E., Jiang H., Parsadanian M., et al. ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. J Biol Chem 279 (2004) 40987-40993
91. Hirsch-Reinshagen V., Zhou S., Burgess B.L., et al. Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain. J Biol Chem 279 (2004) 41197-41207
92. Xu Q., Bernardo A., Walker D., et al. Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus. J Neurosci 26 (2006) 4985-4994
93. Koldamova R., Staufenbiel M., and Lefterov I. Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice. J Biol Chem 280 (2005) 43224-43235
94. Hirsch-Reinshagen V., Maia L.F., Burgess B.L., et al. The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease. J Biol Chem 280 (2005) 43243-43256
95. Wahrle S.E., Jiang H., Parsadanian M., et al. Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. J Biol Chem 280 (2005) 43236-43242
96. Wahrle S.E., Jiang H., Parsadanian M., et al. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest (2008) Epub ahead of print
97. Adighibe O., Arepalli S., Duckworth J., et al. Genetic variability at the LXR gene (NR1H2) may contribute to the risk of Alzheimer's disease. Neurobiol Aging 27 (2006) 1431-1434
98. Zelcer N., Khanlou N., Clare R., et al. Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors. Proc Natl Acad Sci U S A 104 (2007) 10601-10606
99. Piraino G., Cook J.A., O'Connor M., et al. Synergistic effect of peroxisome proliferator activated receptor-gamma and liver X receptor-alpha in the regulation of inflammation in macrophages. Shock 26 (2006) 146-153
100. Calkin A.C., Forbes J.M., Smith C.M., et al. Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects. Arterioscler Thromb Vasc Biol 25 (2005) 1903-1909
101. Llaverias G., Rebollo A., Pou J., et al. Effects of rosiglitazone and atorvastatin on the expression of genes that control cholesterol homeostasis in differentiating monocytes. Biochem Pharmacol 71 (2006) 605-614
102. Yue L., Rasouli N., Ranganathan G., et al. Divergent effects of peroxisome proliferator-activated receptor gamma agonists and tumor necrosis factor alpha on adipocyte ApoE expression. J Biol Chem 279 (2004) 47626-47632
103. Arakawa R., Hayashi M., Remaley A.T., et al. Phosphorylation and stabilization of ATP binding cassette transporter A1 by synthetic amphiphilic helical peptides. J Biol Chem 279 (2004) 6217-6220
104. Mauch D.H., Nagler K., Schumacher S., et al. CNS synaptogenesis promoted by glia-derived cholesterol. Science 294 (2001) 1354-1357
105. Nathan B.P., Jiang Y., Wong G.K., et al. Apolipoprotein E4 inhibits, and apolipoprotein E3 promotes neurite outgrowth in cultured adult mouse cortical neurons through the low-density lipoprotein receptor-related protein. Brain Res 928 (2002) 96-105
106. DeMattos R.B., Curtiss L.K., and Williams D.L. A minimally lipidated form of cell-derived apolipoprotein E exhibits isoform-specific stimulation of neurite outgrowth in the absence of exogenous lipids or lipoproteins. J Biol Chem 273 (1998) 4206-4212
107. Fagan A.M., Bu G., Sun Y., et al. Apolipoprotein E-containing high density lipoprotein promotes neurite outgrowth and is a ligand for the low density lipoprotein receptor-related protein. J Biol Chem 271 (1996) 30121-30125
108. Holtzman D.M., Pitas R.E., Kilbridge J., et al. Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-derived neuronal cell line. Proc Natl Acad Sci U S A 92 (1995) 9480-9484
109. Nathan B.P., Bellosta S., Sanan D.A., et al. Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science 264 (1994) 850-852
110. Brodbeck J., Balestra M.E., Saunders A.M., et al. Rosiglitazone increases dendritic spine density and rescues spine loss caused by apolipoprotein E4 in primary cortical neurons. Proc Natl Acad Sci U S A 105 (2008) 1343-1346
111. Akiyama H., Barger S., Barnum S., et al. Inflammation and Alzheimer's disease. Neurobiol Aging 21 (2000) 383-421
112. Cooper N.R., Bradt B.M., O'Barr S., et al. Focal inflammation in the brain: role in Alzheimer's disease. Immunol Res 21 (2000) 159-165
113. Rogers J., Webster S., Lue L.F., et al. Inflammation and Alzheimer's disease pathogenesis. Neurobiol Aging 17 (1996) 681-686
114. Rogers J., and Shen Y. A perspective on inflammation in Alzheimer's disease. Ann N Y Acad Sci 924 (2000) 132-135
115. Colangelo V., Schurr J., Ball M.J., et al. Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: transcription and neurotrophic factor down-regulation and up-regulation of apoptotic and pro-inflammatory signaling. J Neurosci Res 70 (2002) 462-473
116. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response?. Nat Med 12 (2006) 1005-1015
117. Wyss-Coray T., and Mucke L. Inflammation in neurodegenerative disease-a double-edged sword. Neuron 35 (2002) 419-432
118. Bernardo A., and Minghetti L. PPAR-gamma agonists as regulators of microglial activation and brain inflammation. Curr Pharm Des 12 (2006) 93-109
119. Heneka M.T., and Landreth G.E. PPARs in the brain. Biochim Biophys Acta 1771 (2007) 1031-1045
120. Heneka M.T., Klockgether T., and Feinstein D.L. Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. J Neurosci 20 (2000) 6862-6867
121. Loane D.J., Deighan B.F., Clarke R.M., et al. Interleukin-4 mediates the neuroprotective effects of rosiglitazone in the aged brain. Neurobiol Aging (2007)